Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma

Verburg, Frederik A.; Dietlein, Markus; Laßmann, Michael; Luster, Markus; Reiners, Christoph

doi:10.1007/s00259-008-0997-5

Cited by 30 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, until evidence from randomized trials has assessed the long-term prognostic impact of RAI, we are convinced and still believe that, as stated before for cancer [10,19], postoperative RAI remains an eminently sensible idea, not just for most DTC patients but also for patients with benign thyroid disease.…”

mentioning

confidence: 94%

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

Verburg

Hoffmann

Iakovou

et al. 2019

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 94%

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

Verburg

Hoffmann

Iakovou

et al. 2019

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

“…The effects of the presence of lymph node metastases on thyroid cancer prognosis are known. Especially the presence of bilateral or cervical lymph node metastases or invasion at lymph node capsule are bad prognostic features increasing the risk of regional and distant metastases (7,17). Machens et al (18) found the probability of lymphogenic micrometastasis significantly increased in papillary thyroid cancer above a tumor diameter cut-off of 5 mm.…”

Section: Discussionmentioning

confidence: 99%

“…Remnants of thyroid tissue after thyroidectomy are also treated by I-131. Elevated levels of serum Tg (≤2 ng/ml), is a specific indicator with high sensitivity and means presence of residual thyroid tissue, metastatic focus or recurrence (4,7,8). In addition,post-ablation whole-body scintigraphy provides the detection of unknown metastatic foci and treatment of microscopic tumor foci (9).…”

Section: Introductionmentioning

confidence: 99%

The Evaluation of Microcarcinoma in Differentiated Thyroid Cancers According to Old and New TNM Classification

Hasbek

Turgut²,

Erselcan³

et al. 2011

MIRT

View full text Add to dashboard Cite

Objective: In this study, we aimed to evaluate the tumor size for proximal and distant metastases when the new and old TNM classification is taken into account in differentiated thyroid cancers.Material and Methods: Two hundred sixty eight patients diagnosed with thyroid carcinoma, undergoing bilateral total or subtotal thyroidectomy treated with high doses of I-131 were examined retrospectively. The data of these patients were compared after classification, according to tumor size <1 cm and <2 cm, lymph node metastases thyroid and tumor capsule invasion at the time of diagnosis, and accumulation of abnormal activity in post I-131 treatment whole-body scan. I-131 uptakes besides physiological and thyroid bed were considered as abnormal activity uptakes.Results: A total of 268 patients with average age of 19-82 yrs (mean: 47.0±13.8 yrs) were included in the study. At postoperative histopathological evaluation, 228 (85.1%) of patients were reported as papillary, 13 (4.9%) as follicular, 23 (8.6%) as well differentiated tumor of unknown malignant potential, 2 (0.7%) as insular and 2 (0.7%) as Hürthle-cell carcinoma. In patients with known tumor size, 96 of 207 (46.4%) patients' tumor size was <1 cm and in 111 (53.6%) >1 cm. In the same group, according to the revised TNM classification, in 149 of 207 patients (72%) the tumor size was <2 cm, whereas in 58 (28%) >2 cm. Of 187 patients with negative lymph nodes, 15 (8%) showed abnormal activity accumulation in the first post I-131 treatment whole-body scan and 10 (40% of 25 patients) positive lymph node (p<0.05) involvement.Conclusion: Since the treatment of patients with microcarcinoma is controversial, tumor size should not be the only factor considered in patients with differentiated thyroid cancer Tissue tumor invasion, age, gender and multifocality should also be taken into account.Conflict of interest:None declared.

show abstract

“…61,64,65 Additionally, considering the multiclonal nature of many DTCs, 66 ablation of healthy thyroid cells might prevent neoplastic transformation from occurring again. 67 As an added bonus, 131 I ablation enables sensitive post ablation whole-body scanning to detect previously unknown persistent locoregional disease or distant metastases. 68,69 The latter does not, however, in itself constitute a goal or j ustification of 131 I ablation.…”

Section: Extent Of Surgerymentioning

confidence: 99%

Differentiated thyroid cancer—personalized therapies to prevent overtreatment

2014

Self Cite

View full text Add to dashboard Cite

The concept of individualized therapy is rapidly gaining recognition in the management of patients with differentiated thyroid cancer (DTC). This Review provides an overview of the most important elements of this paradigm shift in DTC management and discusses the implications for clinical practice. In the majority of patients with DTC who have an inherently good prognosis, the extent of surgery, the dosage of (131)I therapy and the use of levothyroxine therapy are all aspects suitable for individualization, on the basis of both the stage of disease and the response to treatment. In individuals with advanced disease, newer imaging techniques, advances in (131)I therapy and the use of targeted molecular therapies (such as multitargeted kinase inhibitors) have provided new options for the personalized care of patients, for whom until recently no effective therapies were available. Individualized therapies could reduce adverse effects, including the sometimes debilitating hypothyroidism that used to be required before initiation of (131)I treatment, and major salivary gland damage, a common and unpleasant side effect of (131)I therapy. Highly individualized interdisciplinary treatment of patients with DTC might lead to improved outcomes with reduced severity and frequency of complications and adverse effects. However, in spite of ongoing research, personalized therapies remain in their infancy.

show abstract

Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma

Cited by 30 publications

References 42 publications

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

The Evaluation of Microcarcinoma in Differentiated Thyroid Cancers According to Old and New TNM Classification

Differentiated thyroid cancer—personalized therapies to prevent overtreatment

Contact Info

Product

Resources

About